Plasma brain natriuretic peptide, platelet parameters, and cardiopulmonary function in chronic obstructive pulmonary disease

doi:10.12998/wjcc.v9.i36.11165

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 36

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3712)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

235

WORD

114

HTML

1950

Tables (1-6)

383

Sum=2682

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

344

Download

686

Sum=1030

Dec 26, 2021 (publication date) through Mar 7, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Clin Cases. Dec 26, 2021; 9(36): 11165-11172
Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11165

Table 1 World Health Organization criteria for evaluating cardiac function in patients with pulmonary arterial hypertension

Grade	Symptom
I	Daily manual activity is unrestricted.
II	Physical activity is mildly restricted, and the symptoms disappear after taking rest; symptoms of shortness of breath and fatigue gradually develop after performing daily general activities.
III	Physical activity is clearly constrained, and there are no apparent symptoms after taking rest; performing activities that require greater strength than that for daily activities could induce shortness of breath, fatigue, and palpitation.
IV	No physical activity is allowed, especially in those with right heart failure syndrome; resting can also trigger anhelation and fatigue symptoms, and any physical activity can aggravate the abovementioned symptoms.

Table 2 Comparison of plasma brain natriuretic peptide and platelet parameters among the pulmonary heart disease, chronic obstructive pulmonary disease, and control groups

Index	PAH group (n = 52)	COPD group (n = 30)	Controls (n = 30)	F	P value
Plasma BNP (pg/L)	59.93 ± 25.77	32.66 ± 6.45^a	14.13 ± 2.46^a^,^c	65.484	0.000
PLT (×10⁹/L)	122.93 ± 27.25	161.26 ± 32.25^a	198.46 ± 43.69^a^,^c	49.040	0.000
PDW (fL)	19.78 ± 4.96	14.62 ± 2.69^a	9.79 ± 1.62^a^,^c	69.027	0.000
PCT (%)	0.17 ± 0.04	0.21 ± 0.05^a	0.26 ± 0.04^a^,^c	37.817	0.000
MPV (fL)	19.08 ± 5.21	14.65 ± 3.12^a	10.03 ± 2.02^a^,^c	48.422	0.000

^aP < 0.05 vs the pulmonary heart disease group.

^cP < 0.05 vs the chronic obstructive pulmonary disease group.

BNP: Brain natriuretic peptide; COPD: Chronic obstructive pulmonary disease; PLT: Platelet count; PDW: Platelet distribution width; PCT: Plateletcrit; MPV: mean platelet volume.

Table 3 Comparison of the plasma brain natriuretic peptide and platelet parameters in the different pulmonary artery pressure subgroups

Index	Mild group (n = 16)	Moderate group (n = 23)	Severe group (n = 13)	F	P value
Plasma BNP (pg/L)	34.75 ± 11.14	61.18 ± 18.77^a	88.72 ± 16.55^a^,^c	39.806	0.000
PLT (×10⁹/L)	138.39 ± 21.75	122.39 ± 28.66^a	104.86 ± 19.65^a^,^c	6.637	0.003
PDW (fL)	16.78 ± 2.69	19.22 ± 4.2^a	24.47 ± 5.15^a^,^c	13.149	0.000
PCT (%)	0.19 ± 0.04	0.17 ± 0.05	0.16 ± 0.03	1.319	0.277
MPV (fL)	14.70 ± 3.64	19.08 ± 4.12^a	24.46 ± 3.29^a^,^c	23.827	0.000

^aP < 0.05 vs the mild group.

^cP < 0.05 vs the moderate group.

BNP: Brain natriuretic peptide; PLT: Platelet count; PDW: Platelet distribution width; PCT: Plateletcrit; MPV: mean platelet volume.

Table 4 Comparison of plasma brain natriuretic peptide and platelet parameters among the different heart function classification subgroups

Index	I (n = 16)	II (n = 14)	III (n = 13)	IV (n = 9)	F	P value
Plasma BNP (pg/L)	31.15 ± 5.46	53.58 ± 7.49^a	78.99 ± 15.44^a^,^c	93.46 ± 12.05^a^,^c^,^e	88.199	0.000
PLT (×109/L)	143.16 ± 19.45	131.16 ± 20.41^a	107.46 ± 23.58^a^,^c	96.52 ± 20.11^a^,^c^,^e	12.866	0.000
PDW (fL)	15.66 ± 2.13	17.99 ± 3.33^a	22.16 ± 2.68^a^,^c	26.45 ± 4.52^a^,^c^,^e	27.386	0.000
PCT (%)	0.20 ± 0.04	0.17 ± 0.04^a	0.15 ± 0.03^a^,^c	0.13 ± 0.02^a^,^c^,^e	6.817	0.001
MPV (fL)	14.03 ± 2.44	18.16 ± 3.07^a	22.15 ± 4.05^a^,^c	24.05 ± 3.74^a^,^c^,^e	26.531	0.000

^aP < 0.05 vs group I.

^cP<0.05 vs group II.

^eP < 0.05 vs group III.

BNP: Brain natriuretic peptide; PLT: Platelet count; PDW: Platelet distribution width; PCT: Plateletcrit; MPV: mean platelet volume.

Table 5 Analysis of correlation of plasma brain natriuretic peptide and platelet parameters with pulmonary arterial pressure in patients with chronic obstructive pulmonary disease and pulmonary heart disease

Index	r	P value
Plasma BNP (pg/L)	0.783	0.000
PLT (×10⁹/L)	-0.471	0.000
PDW (fL)	0.566	0.000
PCT (%)	-0.216	0.124
MPV (fL)	0.726	0.000

BNP: Brain natriuretic peptide; PLT: Platelet count; PDW: Platelet distribution width; PCT: Plateletcrit; MPV: mean platelet volume.

Table 6 Analysis of correlation of plasma brain natriuretic peptide and platelet parameters with cardiac function classification in the pulmonary heart disease group

Index	r	P value
Plasma BNP (pg/L)	0.929	0.000
PLT (×10⁹/L)	-0.670	0.000
PDW (fL)	0.806	0.000
PCT (%)	-0.553	0.000
MPV (fL)	0.814	0.000

BNP: Brain natriuretic peptide; PLT: Platelet count; PDW: Platelet distribution width; PCT: Plateletcrit; MPV: mean platelet volume.

Citation: Guo HJ, Jiang F, Chen C, Shi JY, Zhao YW. Plasma brain natriuretic peptide, platelet parameters, and cardiopulmonary function in chronic obstructive pulmonary disease. World J Clin Cases 2021; 9(36): 11165-11172
URL: https://www.wjgnet.com/2307-8960/full/v9/i36/11165.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i36.11165